Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM. Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance. Herein, we report a most potent, small molecule, nonphosphorylated STAT3 inhibitor, 31 (SH-4-54) that strongly binds to STAT3 protein (K D = 300 nM). Inhibitor 31 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations. Moreover, in vivo, 31 exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo. This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.

[1]  Z. Nikolovska-Coleska,et al.  Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. , 2010, ACS medicinal chemistry letters.

[2]  P. Yue,et al.  Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. , 2011, Bioorganic & medicinal chemistry letters.

[3]  P. Yue,et al.  Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities , 2009, Chembiochem : a European journal of chemical biology.

[4]  P. Gunning,et al.  Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report , 2011, Anti-cancer drugs.

[5]  U. Schindler,et al.  A high-throughput STAT binding assay using fluorescence polarization. , 1997, Analytical biochemistry.

[6]  U. Cortes,et al.  STAT3 is essential for the maintenance of neurosphere‐initiating tumor cells in patients with glioblastomas: A potential for targeted therapy? , 2011, International journal of cancer.

[7]  P. Yue,et al.  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. , 2011, Bioorganic & medicinal chemistry.

[8]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[9]  T. Berg,et al.  A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. , 2004, Analytical biochemistry.

[10]  S. Weiss,et al.  On-target JAK 2 / STAT 3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells , 2013 .

[11]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[12]  Steven Fletcher,et al.  Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules , 2011, ChemMedChem.

[13]  J. Grandis,et al.  In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy , 2005, Oncogene.

[14]  Ying Zheng,et al.  Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma , 2011, Molecular Cancer Therapeutics.

[15]  C. Aldrich,et al.  Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis. , 2013, Bioorganic & medicinal chemistry.

[16]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[18]  S. Weiss,et al.  On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. , 2013, Neuro-oncology.

[19]  J. Darnell,et al.  Structural bases of unphosphorylated STAT1 association and receptor binding. , 2005, Molecular cell.

[20]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  W. Blankesteijn,et al.  G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors. , 2008, Biotechnology annual review.

[22]  C. Marras,et al.  Glioblastoma‐derived tumorospheres identify a population of tumor stem‐like cells with angiogenic potential and enhanced multidrug resistance phenotype , 2006, Glia.

[23]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[24]  Arlin G. Cameron,et al.  Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. , 2005, Journal of medicinal chemistry.

[25]  S. Weiss,et al.  Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens , 2009, Stem cells.

[26]  A. Tefferi.  JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.

[27]  F. Gage,et al.  Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells , 2011, PloS one.